Previous 10 | Next 10 |
The new data were presented at the International Human Microbiome Consortium Congress 2021 Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative coliti...
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences , a leading clinical-stage ...
Karuna to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022 Results suggest that KarXT can be administered to elderly volunteers at doses which achieve xanomeline blood levels similar to those reported in the Phase 2 EMERGENT-1 t...
Oral IL-22 and other preclinical therapeutic candidates as well as the underlying technology platform to be integrated in the Company’s Wholly Owned Pipeline PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a...
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Thursday, May 27, 2021. All of the resolutions proposed at the Annual General Meeting were duly passed by th...
Analysis showed that treatment for weight management with Plenity resulted in NALFD Fibrosis Score Improvement These data support further clinical investigation using Gelesis’ superabsorbent hydrogel platform for the potential treatment of metabolic-related live...
Funding expected to accelerate commercialization of Akili’s flagship treatment, EndeavorRx™, enable expansion of core technologies to treat acute and chronic cognitive disorders, and drive further research and development of new digital therapeutics PureTech ...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that D...
PureTech Health (PRTC) announces the formation of its clinical advisory board for idiopathic pulmonary fibrosis ((IPF)) and other progressive fibrosing interstitial lung diseases ((PF-ILDs)).The advisory group will work closely with the company in the advancement of its anti-fibroti...
Leading experts in the field will advise on clinical development of PureTech’s lead, wholly-owned product candidate, LYT-100, in idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases PureTech Health plc (Nasdaq: PRTC, LSE: PR...
News, Short Squeeze, Breakout and More Instantly...
Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated...
2024-06-27 14:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, confirms that the Tender Offer announced by the Company on 20 May 2024 is now ...